Searchable abstracts of presentations at key conferences in endocrinology

ea0047oc45 | Innovative Theranostics | Theranostics2016

Glioma tumors grade II/III – local alpha emiters targeted therapy with 213Bi-DOTA-substance P

Krolicki Leszek LK , Morgenstern Alfred AM , Kunikowska Jolanta JK , Koziara Henryk HK , Bartosz Krolicki BK , Jakucinski Maciej MJ , Pawlak Dariusz DP , Apostolidis Constantinos CA , Bruchertseifer Frank FB

Gliomas are a highly heterogeneous group of brain tumours that are refractory to treatment, and highly invasive. The treatment and prognosis depend upon the tumor grade. Treatment of Grade II/III gliomas typically consists of maximal safe resection, followed by external beam radiation therapy. Although less aggressive than GBM, mortality is high with a 5-year survival rate of only 25.9%. Glioma tumors has been demonstrated NK-1 receptor system and substance P can be used as a ...

ea0020p203 | Endocrine tumours and neoplasia | ECE2009

Efficacy and safety of 90Y-DOTATATE therapy in neuroendocrine tumours (NETs)

Sowa-Staszczak Anna , Hubalewska-Dydejczyk Alicja , Kunikowska Jolanta , Krolicki Leszek , Mikolajczak Renata , Pawlak Dariusz , Gilis-Januszewska Aleksandra , Trofimiuk Malgorzata , Stefanska Agnieszka

Therapy with labeled somatostatin analogues is the modern approach to patients with disseminated or unresectable NETs expressing somatostatin receptors (SSTR). Octreotate is the somatostatin analogue with high affinity to SSTR type 2, most commonly present in NETs. The aim of the study was to assess the efficacy and toxicity of peptide receptor radionuclide therapy (PRRT) with the use of 90Y labelled Tyr3-octreotate, (90Y-DOTATATE) in NETs....

ea0014p131 | (1) | ECE2007

Results 90Y-DOTATATE therapy in patients with neuroendocrine tumours (NETs) - own experience

Kunikowska Jolanta , Hubalewska-Dydejczyk Alicja , Sowa-Staszczak Anna , Krolicki Leszek , Ochman Pawel , Mikolajczak Renata , Pawlak Dariusz , Kobylecka Malgorzata , Maczewska Joanna , Huszno Bohdan

In the 1980 s the discovery of expression of somatostatin receptors on NET cells made the use of somatostatin analogues in diagnosis and therapy possible.The aim: Of the study was to assess response of targeted radio-nuclide therapy with radio-labelled somatostatin analogue 90Y-[DOTA0,D-Phe1,Tyr3]-octreotate (DOTATATE) in treatment of disseminated NETs.Material and methods: 12 patients (a...

ea0049ep1445 | Thyroid (non-cancer) | ECE2017

Theranostic management of medullary thyroid cancer (MTC) with (111In/177Lu) CP04: how close are we to a clinical solution?

Hubalewska-Dydejczyk Alicja , Erba Paola , Decristoforo Clemens , Zaletel Katja , Mikolajczak Renata , Maecke Helmut , Maina-Nock Theodosia , Konijnenberg Mark , Kolenc-Peitl Petra , Trofimiuk-Muldner Malgorzata , Przybylik-Mazurek Elwira , Virgolini Irene , Pawlak Dariusz , de Jong Marion , Froberg Alide C , Rangger Christine , Goebel Georg , Scarpa Lorenza , Skorkiewicz Konrad , Lezaic Luka , Garnuszek Pirotr , Sowa-Staszczak Anna , Nock Berthold A , Bergant Damijan , Rep Sebastijan , Glowa Boguslaw

Effective targeted therapy for advanced endocrine malignancies is a goal of modern endocrinology. We herein present promising results of the first phase of clinical part of European project (Gran-T-MTC) aimed to assess the safety of gastrin analogue CP04 (DOTA-(DGlu)6-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) i.v. administration in dose (50 μg) useful for translation to 177In-CP04 for PRRT. CP04 has been selected for MTC therapy based on a high CCK-2 receptor...